Brief: Medincell-Teva Updates On Pivotal Clinical Phase 3 Of Investigational Olanzapine LAI

Medincell SA

05/09/2024 06:32

Sept 5 (Reuters) - Medincell SA  MEDCL.PA :
    * MEDINCELL'S PARTNER TEVA PROVIDES NEW UPDATE ON PIVOTAL
CLINICAL
PHASE 3 OF INVESTIGATIONAL OLANZAPINE LONG-ACTING INJECTABLE
(LAI)
    * CONFIRMATION THAT FULL PHASE 3 SAFETY RESULTS ARE ON TRACK
FOR
H2 2024
    * NO PDSS* OBSERVED AFTER COMPLETION OF C.99% OF TARGETED
INJECTIONS FOR SUBMISSION

Source text for Workspace:  ID:nBw4zW9K0a 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))